← boardnext 2027-06-30
BLTE
Belite Bio, Incdistress 2/10 · well-funded / low risk$157.69+0%today-17% from 52w high
Lead: Stargardt Disease 1 · target RBP4
Revenue
pre-revenue
Liquidity
$353M
Runway
9.5 yrs
Shares 1y
0%
Price & events
-1.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+4.7%
1W
+8.7%
1M
-4.1%
3M
-4.2%
6M
+153.1%
1Y
+214.8%
2Y
—
5Y
+1389.1%
All
Overview
- Market Cap
- $6.20B
- Volume
- 10.68K
- 52 Week Range
- $59.67 – $190
- Total Shares
- 39.34M
- Float Shares
- 18.47M
- Short %
- 6.31%
- % Held by Insiders
- 44.27%
- % Held by Institutions
- 23.65%
- RVOL
- 0.05x
- Beta
- -1.23
Pipeline stages · 1 programs
Tinlarebant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-30 Estimated 50% readout ~2027-09-13 | Phase 3 | Tinlarebant | Geographic Atrophy | — | active not recruiting |
| 2028-02 Estimated 50% readout ~2028-04-16 | Phase 2/3 | Tinlarebant | STGD1, Stargardt Disease 1 | — | active not recruiting |
| 2025-08-04 | Phase 3 | Tinlarebant | Stargardt Disease 1 | 104 | completed |
Catalyst news & presentations · 1
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $211 (+33% upside) · 8 analysts
- 2026-06-15HC Wainwright & Co.Buy
- 2026-05-26MizuhoOutperform
- 2026-05-21HC Wainwright & Co.Buy
- 2026-04-22HC Wainwright & Co.Buy
- 2026-04-13HC Wainwright & Co.Buy
- 2026-03-03Morgan StanleyOverweight
Competitors — RBP4
- none identified
Recent news
- 2026-07-22Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - Yahoo Finance
- 2026-07-22Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com Nigeria
- 2026-07-20Why Is Belite Bio Stock Gaining Monday? - Benzinga
- 2026-07-20Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com Nigeria
- 2026-07-20Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
- 2026-07-20Belite Bio Announces Oral Presentation at the ASRS Annual - GlobeNewswire
- 2026-07-20Belite Bio Announces Oral Presentation at the ASRS Annual - GlobeNewswire
- 2026-07-20Belite Bio (BLTE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BLTE - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.